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Abstract: 
PURPOSE: 
Recent evidence suggests that the tau radiotracer [18F]-THK-5351 displays high affinity for the monoamine 
oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([18F]-AV-1451), we previously 
reported that non-demented Parkinson’s disease patients show off-target binding in subcortical structures, 
but no appreciable cortical uptake. However, 59% of these patients were receiving MAO-B inhibitors at the 
time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect 
flortaucipir binding. 
PROCEDURES: 
We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson’s disease 
patients who received MAO-B inhibitors with those who did not.  
RESULTS: 
Sixteen of 27 Parkinson’s disease patients received MAO-B inhibitors at the time of scan. We found no 
significant flortaucipir uptake differences between the groups at voxel or regional levels. 
CONCLUSION: 
Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, 
MAO-B does not appear to be a significant binding target of flortaucipir. 
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Introduction 
Flortaucipir, also known as [18F]-AV-1451 or [18F]-T807, has been shown to detect cortical tau pathology in 
the form of neurofibrillary tangles, in increasing amounts over the spectrum from healthy aging, mild 
cognitive impairment, and Alzheimer’s disease[1–4]. The tracer, however, also displays age-related off-
target binding of unclear origin in the basal ganglia, and to neuromelanin rich cells of the substantia nigra 
and retina[5–7]. Another tau-tracer, [18F]-THK-5351, with a similar uptake pattern to flortaucipir at a 
macroscopic level, was recently shown to be a substrate for monoamine oxidase type B (MAO-B) in vivo 
and in autoradiography and its binding was blocked by the MAO-B inhibitor selegiline[8]. Interestingly, 
positron emission tomography (PET) scans with the MAO-B marker [11C]-deprenyl[9] show similarities with 
[18F]-THK-5351 and flortaucipir PET scans. Further, brain MAO-B is known to increase with age[10]. It is, 
therefore, conceivable that MAO-B is also a target of flortaucipir. 
We have previously reported on the flortaucipir binding pattern of a group of patients with Parkinson’s 
disease[5, 11]. 59% of these tau negative patients who had flortaucipir PET had received MAO-B inhibitors 
within 24 hours of their scan, as we were unaware at that time of the possible influence of MAO-B activity 
on flortaucipir binding. With the purpose of investigating the validity of our previous studies, and for future 
reference in clinical use, we retrospectively investigated if MAO-B inhibitor use in clinical doses affects their 
flortaucipir binding. 
Materials and Methods 
Twenty-seven Parkinson’s disease patients who have been previously described[5, 11] were retrospectively 
stratified based on their MAO-B inhibitor use based on their lists of medication at the time of the 
flortaucipir scan[5]. The study was approved by the regional ethics committee and all subjects signed an 
informed consent form. Scan coregistration, volume of interest definition, and data extraction were 
performed with PMOD software (PMOD, Zürich, Switzerland), as previously described[5].  
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Regional statistical analysis was performed with Stata 13.1 (StataCorp LP, Texas). Voxel wise analyses were 
performed with SPM12 (http://www.fil.ion.ucl.ac.uk/spm/), using a linear regression model with 
standardized uptake values as the dependent variable and group and age as independent variables. Family-
wise error corrections were used for voxel wise analyses. Continuous and categorical variables were 
interrogated using Student’s t-test and Fisher’s exact test, respectively. P-values <0.05 were considered 
statistically significant. 
Results 
Six of 27 Parkinson’s disease patients reported taking selegiline (one 5 mg, four 10 mg, and one 15 mg per 
day) and ten other patients reported taking rasagiline (all 1 mg per day) on the day of scan. See TABLE 1 for 
demographics. 
No significant between group differences in mean flortaucipir uptake were seen in regional (FIGURE 1) or 
voxel wise analyses (FIGURE 2). A more liberal, explorative approach with simple inspection of t-maps 
revealed no meaningful trends in group differences. 
Discussion 
Our results suggest that flortaucipir PET is not significantly affected by oral ingestion of MAO-B inhibitors at 
clinically prescribed doses. It, therefore, seems unlikely that MAO-B binding is contributing to the basal 
ganglia signal seen in flortaucipir PET images. However, we cannot rule out non-competitive binding of 
flortaucipir to a different binding site on MAO-B, which may be unaffected by the MAO-B inhibitors in 
clinical use. 
In an early paper on flortaucipir (then known as [18F]-T807), Xia and colleagues[12] found that “no inhibition 
was seen for MAO-A and MAO-B at a 1-μM concentration”. This was specifically tested, as the group of 
compounds the tracer belongs to, the carbazoles, was found to contain potent MAO inhibitors. Later, in a 
conference presentation, Vermeiren and colleagues reported affinity of flortaucipir for MAO-A (KD≈1.5 nM) 
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and MAO-B (KD≈30 nM)[13], though this has not to our knowledge been published in detail. Several 
unsuccessful attempts have been made to identify other targets using autoradiography[6, 7, 14, 15]. 
Following the recent paper by Kok Ng and colleagues describing up to a 50% reduction in [18F]-THK-5351 
signal following selegiline administration, we felt it was appropriate to revisit the potential for a significant 
effect of MAO-B inhibitor use on flortaucipir PET. A characteristic pattern of heterogenous distribution with 
relatively higher signal in the striatum, globus pallidus, and thalamus is shared between flortaucipir[2, 16], 
[18F]-THK-5351[8] and [18F]-labeled selegiline ([18F]-fluorodeprenyl-D)[17]. Further, the binding of these 
three tracers all extend to include cortical areas in Alzheimer’s disease (flortaucipir[1], [18F]-THK-5351[18] 
and [11C]-labelled selegiline ([11C]-deuterium-L-deprenyl)[9]). One notable exception to this pattern is that 
flortaucipir has additional off-target binding in the substantia nigra[7], presumed to be neuromelanin, and 
also to the choroid plexus[19]. The similar brain distributions of flortaucipir uptake and MAO-B activity and 
the age dependency of both suggests the possibility of significant MAO-B binding by flortaucipir [10]. Also, 
the paradoxical pattern of flortaucipir PET in progressive supranuclear palsy patients, with an absence of 
binding in cortex but increased binding in the basal ganglia compared with healthy controls, could be 
compatible with MAO-B binding of this agent [6, 16, 20–22]. The observations in progressive supranuclear 
palsy may be explained by increased amounts of MAO-B from associated gliosis, rather than binding to the 
4-repeat tau present. The linear tau seen in progressive supranuclear palsy has been autoradiographically 
shown to have a low affinity for flortaucipir as compared to the mixed 3 and 4 repeat paired helical tau of 
Alzheimer’s disease[7, 14]. Further, the unexplained increased flortaucipir binding in the putamen of 
multiple system atrophy[23], could also be attributable to concomitant gliosis and raised MAO-B. Indeed, 
Shcherbinin and colleagues reported findings suggesting “either additional off-target binding in the 
putamen or a second binding site with different kinetics”[24]. We have previously reported reduced off-
target flortaucipir binding in the substantia nigra of Parkinson’s disease[5], compatible with a decrease in 
neuromelanin content[25]. While similar pigment-like compounds increasing with age have been described 
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in the basal ganglia[26], Passamonti and colleagues found no neuromelanin-containing cells in the basal 
ganglia in patients or controls with relatively increased in vivo flortaucipir PET binding in the same area[6]. 
If MAO-B is a significant target of flortaucipir at levels used for in vivo PET, it diminishes the tracer’s value 
as a marker of tau and an outcome measure in pharmaceutical trials. Further, as brain MAO-B (and -A) is 
reduced by smoking[27], present smoking status would have to be recorded for clinical use. As MAO-B 
appears to be a significant target of [18F]-THK-5351, while flortaucipir does not, we expect higher affinity 
between [18F]-THK-5351 and MAO-B, than between flortaucipir and MAO-B. However, we are not aware of 
any publication reporting results of MAO-B to [18F]-THK-5351 binding assays, which would allow such 
comparison. While a relative difference in affinity of the two tau tracers for MAO-B would explain the 
findings of the present study, the off-target binding of flortaucipir in the basal ganglia still remains to be 
elucidated. The importance of identifying this target is underlined by the example of [18F]-THK-5351, i.e. the 
off-target may co-localize with the primary target of tau in neurofibrillary tangles. 
According to Vermeiren and colleagues[13] and the investigator’s brochure, flortaucipir displays  higher 
affinity for MAO-A than MAO-B[13]. This affinity for MAO-A may be less problematic as MAO-A occurs in 
lower concentration, and does not show age-dependent increases[10]. Further, the increase of MAO 
activity from astrocytes observed in Alzheimer’s disease, appear to be due to increased MAO-B activity 
alone[28]. To our knowledge, no attempts have been made to block flortaucipir signal using the MAO-A 
inhibitor clorgyline. Clorgyline can, however, be used as a PET-tracer, and shows a pattern of high binding in 
the thalamus and occipital cortex, intermediate values in basal ganglia, frontal, and temporal cortices and 
little binding in the cerebellum[29, 30]. Another MAO-A tracer, [11C]-harmine[31], displays a similar 
pattern[32]. Hence, the binding pattern of these MAO-A tracers does not appear to match the pattern 
shown by flortaucipir. 
This study has several limitations. First, we did not have paired blocked and unblocked patient data. 
However, Kok Ng and colleagues showed robust [18F]-THK-5351 reductions of >50% in the thalamus and 
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basal ganglia after administration of clinical selegiline doses. The comparable 95% confidence intervals of 
mean thalamic flortaucipir decrease following MAO-B inhibitor administration in our study was [-11.2%; 
24.0%]. Second, we did not have an exact record of when the test subjects received their last dose of MAO-
B inhibitor prior to the scan or for how long they had received MAO-B inhibitors. Using [11C]L-deprenyl, 
Fowler and colleagues demonstrated that one week of treatment with selegiline in clinical doses (10 mg per 
day) blocks more than 95% of binding to MAO-B. This corresponds to a 70-80% reduction in overall brain 
SUV, due to increased tracer availability from blocking elsewhere. Following selegiline withdrawal, MAO-B 
recovered with a half-time of 40 days[33, 34]. Consequently, the impact of a patient having missed a single 
or even two doses before scan would be negligible. Third, the use of chronic administration in our study, 
rather than acute treatment as in Kok Ng et al., may cause unforeseen effects, including compensatory 
regulation of the MAO-A and -B enzymes, which could ultimately affect the results. Fourth, two different 
MAO-B inhibitors with different structures and metabolites were used. Considering the large effect size 
described by Kok and colleagues, we would expect to see at least a bimodal distribution in the MAO-B 
inhibitor group, even if only selegiline and not rasagiline was an effective blocker of flortaucipir binding. 
Finally, as none of our Parkinson’s disease patients appeared to be tau-positive, we were unable to 
investigate if the specific binding from areas with neurofibrillary tangles was blockable with MAO-B 
inhibitors[9, 35]. 
Conclusion 
Several observations from human PET studies suggest that MAO-B as well as tau could be a target of 
flortaucipir binding. However, after retrospectively comparing Parkinson’s disease patients receiving clinical 
doses of MAO-B inhibitors with those who did not, we were unable to detect any significant effect of MAO-
B inhibition on flortaucipir uptake. Further studies are needed to investigate the origin of the off-target 
binding of flortaucipir. 
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Figure Legends 
FIGURE 1. Key regional standardized uptake values (SUV) from all subjects, no age correction. Monoamine 
oxidase type B (MAO-B). 
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FIGURE 2. Mean standardized uptake values (SUV) of the two groups, corrected to age 70 years old. 1: 
Caudate nucleus. 2: Putamen. 3: Choroid plexus. 4: Pallidum. Monoamine oxidase type B (MAO-B).  
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TABLE 1 – Demographics 
Parkinson’s disease group: No MAO-B inhibitor With MAO-B inhibitor 
Study group, N 11 16 
PD-MCI/nonMCI 5/6 4/12 
Age 70.6±8.3 66.7±5.0 
Female/Male 2/9 2/14 
Smoker: Never/Previous 8/3 10/6 
Montreal Cognitive Assesment 26.1±2.4 26.9±2.5 
Mini-Mental State Examination 28.1±1.4 28.6±1.5 
Unified Parkinson’s Disease Rating Scale, Part 3 21.4±12.7 24.5±13.9 
Hoehn & Yahr stage 2.0±0.6 2.3±0.6 
Disease duration, years 5.4±3.7 5.5±3.7 
Mean ± standard deviation. No significant differences as tested with Student’s t-test or Fisher’s exact test. 
Parkinson’s Disease with Mild Cognitive Impairment (PD-MCI). 
